BioCentury

7:00 AM GMT, Jun 29, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Unloading HCV

Innate Pharma S.A. was to announce the first clinical data this week for a gamma-9 delta-2 T cell agonist to treat HCV. The results provide the first human proof of concept for its candidate against the target, although the company will need to do further work to show a clinical benefit and determine where in the HCV regimen IPH 1101 could

Read the full 617 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.